Erectile Dysfunction Market Assessment & Analysis 2007-2022

Erectile Dysfunction Market Assessment & Analysis 2007-2022

The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of 4.9% for the period 2006-2012. The ED market contains three leading drugs Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, is the most popular and recognised brand on the market.

Furthermore, high revenues are predicted by visiongain for the top three ED drugs, with Cialis reaching blockbuster status by 2007. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints. The purpose of this market analysis by visiongain is to examine prospects for Erectile Dysfunction (ED) drugs from 2007-2022, including sales forecasts for leading pharmaceutical products.

Most men experience ED at some points in their lives usually by the age of 40, but are not necessarily psychologically affected by it. Some men, however, experience chronic and complete ED. Over 150 million men worldwide are unable to achieve and maintain an erection adequate for satisfactory sexual intercourse; visiongain expects this figure to double by 2020. Despite its commonplace occurrence, ED is a notoriously under-reported, under-recognised, and an under-treated chronic illness.
It is estimated that 85% to 90% of all ED goes undiagnosed.

The ED Market Report examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The ED Market concentrates on the following essential aspects of the market:

* Discussion of the current pharmaceutical market
* Forecast of the worldwide pharmaceutical market from 2007-2012
* Drivers and restraints facing the ED market
* Opportunities and threats facing the ED market
* Growth of the ED drugs market between 2007-2012
* Commercial prospects for the market-leading drugs, with sales
forecasts from 2007-2012
* The potential of generics manufacturers to penetrate this market
* Pipeline developments with blockbuster potential
* Currently marketed drugs with blockbuster potential
* Discussion of unmet therapeutic needs and relative advantages of
products

Why you should buy this report:

* To receive a comprehensive analysis of the prospects for ED
drugs from 2007-2012
* To discover predicted revenues, growth rates and other key
metrics for leading pharmaceutical treatments from 2007-2012
* To determine key activities of leading companies
* To discover `hot` pipeline developments and up-and-coming
products
* To determine the forces that influence the market for ED
products:
* Competitive characteristics of the market
* Drivers
* Restraints
* Strengths, weaknesses, opportunities and threats (SWOT analysis)
* To find out where the ED market is heading - both
technologically and commercially

Why You Must Buy This Report:
This report features tables, graphs and charts, news, insights, the past and present developments in the ED Market. Amongst the catalogue of products in the ED pipeline is transdermal therapies. Neew innovative products for ED has generated a high level of interest from; top-tier companies, the major players in the ED circle and niche companies alike.


This visiongain report is the single tool to equip you with the latest trends in all regional markets and why drug companies are aiming for a new generation of drugs. Visiongain recommends this astute report to the major players in the field as it will arm you with the clinical challenges that larger companies face to date, thus the rising inherent cost of R&D expenditure to in order meet the requirements set by major regulatory authorities for larger evidence of clinical data before any authorisation.

The ED Market Assessment & Analysis 2007-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics.

Unique benefits to you when you order this report:
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables

Chapter 1 Executive Summary

Chapter 2 Introduction - The Erectile Dysfunction Market Will See Large Growth Rates Throughout the Period, 2007-2012
2.1 The Viagra Revolution
2.2 Erectile Dysfunction Defined
2.3 ED Prevalence is Increasing
2.4 Male Hormonal Changes Due to Age
2.5 How an Erection Occurs
2.6 Penile Anatomy and Erection
2.7 Primary and Secondary ED
2.8 The Causes of Secondary ED
2.9 ED Due to Systemic Diseases and Ageing 2.10 Neurogenic Erectile Dysfunction
2.11 Vascular Causes of Erectile Dysfunction
2.12 Drug-Induced Erectile Dysfunction
2.13 Summary of All ED Treatments
2.14 Drug Therapy
2.14.1 Mechanism of Action of PDE-5 Inhibitors
2.14.2 Viagra (Pfizer)
2.14.3 Cialis (Eli Lilly/Icos)
2.14.4 Levitra (GSK/Bayer AG)

Chapter 3 The World Market for ED Drugs
3.1 The ED Market Will See Large Growth Rates
3.2 Viagra Will Lose Dominance of the ED Market
3.3 Cialis Will Achieve Blockbuster Status
3.4 Viagra Will Lose Market Dominance to Cialis
3.5 Levitra Shows Strong Growth
3.6 Shortest Time to Erection is a Major Market Advantage
3.7 Brand Awareness Will Play a Key Part in Maintaining Viagra's Position in the Market
3.8 Brand Switching Will Increase Individual Drug Sales But Not Expand the Market
3.9 Market Expansion Depends on Persuading ED Men to Seek Treatment 3.10 Pfizer Currently Leads the ED Market
3.11 The US Dominates the World Market for ED Drugs

Chapter 4 Forces Affecting the ED Market
4.1 SWOT Analysis of the ED Market
4.2 An Expanding Patient Population Constitutes the Principal Driver in the ED Market
4.3 The Principal Restraints in the ED Market
4.4 Major Success in the ED Drugs Market and Opportunities to Target
4.5 Adverse Events Over ED Drugs
4.5.1 FDA Revise Label Changes to ED Drugs After Reported Sudden Hearing & Vision Loss
4.5.2 FDA Immediately Recall `Natural` ED Drugs After Major Concerns Over Safety
4.5.3 Studies Link ED to Heart Disease and Smoking
4.6 Lack of Adequate Reimbursement Limits Potential of ED Drugs
4.7 ED Surgery - A Last Resort When Drug-Based Treatments Fail
4.7.1 Penile Venous Surgery
4.7.2 Penile Arterial Revascularization
4.7.3 Penile Implants
4.7.4 Internal Penile Pump
4.8 ED Awareness is Key for Market Expansion
4.9 Uprima (Apomorphine) is a Market Failure

Chapter 5 Female Sexual Dysfunction (FSD) and Future Market Possibilities
5.1 Female Sexual Arousal
5.2 Over 45% of All Women Will Experience Some Degree of FSD
5.3 Genital Vascular Congestion Essential for Normal Sexual Function in Both Men and Women
5.4 The Medical Causes of Female Sexual Dysfunction
5.5 Medical Drugs Can Cause FSD
5.6 There are Times in a Women's Life of Natural Decreased Sexual Desire
5.7 The Treatments for Female Sexual Dysfunction
5.8 The Role of Estrogen and Progesterone in Female Sexual Desire is not Understood
5.9 The Role of Testosterone in Female Sexual Desire is Not Clear 5.10 The Treatment of Female Sexual Arousal Disorders
5.11 Anorgasmia Responds Well to Therapy
5.12 The Successful Treatment for Dyspareunia Approaches 90%
5.13 The Pharmacological Treatment of FSD and Future Market Possibilities

Chapter 6 Pipeline Developments in the Erectile Dysfunction Market
6.1 Abbott's ABT- 670 in Phase I Trials for ED
6.2 Agents in Phase II of Clinical Development
6.2.1 Pfizer's UK 369003
6.2.2 Inotek's INO 1001
6.2.3 Schering-Plough's Dasantafil
6.2.4 Vivus' Avanafil
6.2.5 Abbott's ABT-724
6.3 SK Chemicals' Mirodenafil in Pre-Registration for ED
6.4 New Drugs for ED Must Have a Short Onset Time
6.5 Discussion of Current Pipeline Developments
6.6 Summary of Pipeline Drugs for ED, Phase I and Above

Chapter 7 The Counterfeit ED Drugs Market
7.1 Drug Counterfeiting: An Overview
7.2 The Different Types of Counterfeit Drugs
7.3 Viagra Counterfeits
7.4 Country Specific Patent Laws and How it can Influence Drug
Counterfeiting
7.5 The Growth of Internet Pharmacies Has Aided Viagra Sales
7.6 The Privacy Factor as a Driver of Online Sales
7.7 Online Viagra
7.8 Internet Erectile Dysfunctional Drugs Sales
7.9 Combating the Counterfeiters


Chapter 8 Conclusion
8.1 ED is a Serious Condition with High Prevalence
8.2 ED Market Analysis
8.3 Market Drivers
8.4 Market Restraints
8.5 New Products May Not Expand the Market Further
8.6 The Time to Erection is the Most Important Aspect of Any Novel ED
Drug
8.7 The Key to Market Expansion is to Get More ED Men to Seek Medical
Advise
8.8 Strategies for Marketing: Changing Men's Minds
8.9 Outlook for the Future of the ED Market

List of Tables
Table 1.1 Top ED Drugs Revenue ($m), 2006
Table 2.1 Major Drug Therapies for ED, 2006
Table 2.2 Viagra, Cialis, and Levitra Revenues ($m) and Market Share
(%), 2006
Table 3.1 The Total World ED Drugs Market Forecast ($m), 2007-2012
Table 3.2 Worldwide Revenues ($m) for ED Drugs, 2007-2012
Table 3.3 The Worldwide Market Share by Revenue (%) for ED Drugs,
2007-2012
Table 3.4 Viagra, Levitra and Cialis: Specific Product Advantages, 2007
Table 3.5 Top 10 Leading Companies in the ED Market, Revenue ($m) and
Market Share (%), 2006
Table 3.6 Market Share by Country Region by Revenue (%), 2006
Table 4.1 A SWOT Chart for the ED Market
Table 5.1 Types of Female Sexual Dysfunction and Prevalence
Table 5.2 Drugs that Cause Decreased Sexual Desire
Table 5.3 Drugs that Cause Decreased Sexual Arousal
Table 6.1 Agents in Phase II of Clinical Development for ED, 2007
Table 6.2 Summary of Pipeline Drugs for ED, Phase I and Above, 2007

List of Figures
Figure 2.1 Worldwide Revenues ($m) for the ED Market, 2007-2012
Figure 3.1 Total ED Drugs World Market Revenue Forecast ($m), 2007-2012
Figure 3.2 Worldwide Revenues ($m) for ED Drugs, 2007-2012
Figure 3.3 The Worldwide Market Share (%) By Revenue for Viagra, Levitra
and Cialis, 2007-2012
Figure 3.4 Market Share (%) by Revenue of ED Drugs, 2006
Figure 3.5 Market Share (%) by Revenue of ED Drugs, 2009
Figure 3.6 Market Share (%) by Revenue of ED Drugs, 2012
Figure 3.7 Leading Companies in the ED Market, Market Share (%), 2006
Figure 3.8 Market Share by Country Region (%), 2006
Figure 8.1 Total Sales of ED Drugs ($m), 2007-2012
Figure 8.2 Sales of the Leading ED Drugs ($m), 2007-2012

List of Companies Mentioned
Abbott
Alza
Bayer
Dong-A
Eczacibasi
FDA
Genentech
GSK
In2Gen
Inotek
Johnson & Johnson's
Kohl Medical
Lilly
MHRA
Palatin
Pfizer
Schering-Plough
SK Chemicals
Spimaco
Surface Logix
Synvista
Tanabe
UCB
Vectura
Vivus
WHO